Eli Lilly's New Drug Muvalaplin Reduces Lp(a) by 85.8%!

Eli Lilly and Company recently announced positive results in a Phase 2 clinical trial for muvalaplin, its once-daily oral lipoprotein (a) -- Lp (a) inhibitor. The study results showed that the trial met its primary endpoint, and muvalaplin was able to significantly reduce Lp (a) levels in adult patients, showing significant improvement in the percentage change in Lp (a) levels from baseline to week 12. Data from these studies have been published in the Journal of the American Medical Association (JAMA) and presented at the American Heart Association (AHA) Annual Scientific Meeting 2024.

Muvalaplin is an oral small-molecule drug that works by blocking the interaction of apo (a) with apo B100 while avoiding interaction with the homologous protein plasminogen, thereby inhibiting Lp (a) production.

The analysis showed that muvalaplin (at doses of 10 mg, 60 mg, and 240 mg, respectively) significantly reduced Lp (a) levels in patients evaluated at the primary endpoint at week 12. After adjustment for placebo, a reduction of up to 85.8% was assessed using the full Lp (a) test and up to 70.0% was assessed using the apo (a) test. Specific data are as follows:

With full Lp (a) detection, the reduction of 10 mg, 60 mg and 240 mg doses was 47.6%, 81.7% and 85.8%, respectively.

When apo (a) was used, the reduction of 10 mg, 60 mg and 240 mg doses was 40.4%, 70.0% and 68.9%, respectively.

In addition, muvalaplin achieved a secondary endpoint at all tested doses. In terms of safety, the incidence of adverse events with muvalaplin was comparable to those in the placebo group, and most were minor events, demonstrating its well-tolerated and safe profile.